Pfizer Secures Full FDA Approval for BRAFTOVI in BRAF V600E Colorectal Cancer
FDA granted full approval to Pfizer's BRAFTOVI regimen combining encorafenib, cetuximab and fluorouracil-based chemotherapy for metastatic colorectal cancer patients with BRAF V600E mutation. Phase 3 BREAKWATER data showed a 64.4% objective response rate versus 39.2% in standard care and significant gains in progression-free and overall survival, bolstering global expansion prospects.
1. Full FDA Approval Granted
The U.S. Food and Drug Administration granted full approval to Pfizer’s BRAFTOVI combination regimen of encorafenib, cetuximab and fluorouracil-based chemotherapy for adult patients with metastatic colorectal cancer harboring the BRAF V600E mutation, elevating its status from accelerated to complete approval.
2. Breakwater Trial Results
Approval was based on Phase 3 BREAKWATER trial outcomes demonstrating a 64.4% confirmed objective response rate with BRAFTOVI versus 39.2% in standard-of-care FOLFIRI or mFOLFOX6 regimens, along with statistically significant improvements in progression-free survival and overall survival.
3. Market Expansion Outlook
With full FDA approval secured, Pfizer is pursuing regulatory reviews in Europe and leveraging approvals in multiple countries to drive oncology revenue growth, positioning BRAFTOVI as a first-line treatment in a market segment projected to expand substantially over the coming years.